Biotechnology

GENFLEET-B

Jenffine Biotech Clarifies No Patent Infringement on RAS Inhibitor Against Revolution Medicines

Guokin Securities Rates Jinfang Medicine-B as Buy

Jinfang Pharmaceutical GFH375 Receives Breakthrough Therapy Designation from National Medical Products Administration

JinFang Pharmaceutical-B Releases 2025 Fiscal Year Revenue Growth of 25%

GENFLEET-B released FY2025 Q3 earnings on March 24, 2026 (BJT) with actual revenue of HKD 22.7 M and EPS of HKD -1.7987

GENFLEET-B released FY2024 9 Months Earnings on March 24, 2026 (BJT) with actual revenue of HKD 0 and actual EPS of HKD -19.4455

GENFLEET-B released FY2025 9 Months Earnings on March 24, 2026 (BJT) with actual revenue of HKD 118.78 M and EPS of HKD -4.7238

GENFLEET-B released FY2024 Q3 earnings on March 24, 2026 (BJT) with actual revenue of HKD 58.03 M and EPS of HKD -0.4724

GENFLEET-B released FY2024 Q4 earnings on March 24, 2026 (BJT), with actual revenue of HKD 55.69 M and EPS of HKD -0.4534

GENFLEET-B released FY2025 earnings on March 24 During-Market (BJT), actual revenue HKD 142.38 M (forecast HKD 160.47 M), actual EPS HKD -6.6304 (forecast HKD -3.8901)

GENFLEET-B released FY2025 Q4 earnings on March 24 During-Market (BJT), actual revenue HKD 23.09 M, actual EPS HKD -1.8297

Wellington Management Increases Stake in Junfarmer Biopharma

Jenffine Biopharmaceutical-B to Showcase Preclinical Data of Three Products

Jinfang Pharmaceutical-B to Present Preclinical Data on Three Products at AACR Annual Meeting

Wellington Management Increases Stake in Jinfang Medicine-B

GENFLEET-B to release FY2025 earnings on March 24, 2026, during market hours (BJT), forecast revenue HKD 164.99 M, EPS HKD -3.9997

CMB International Initiates Coverage of JiFang Medicine-B with Buy Rating

Central Economic Work Conference Emphasizes Innovation Leadership in Pharmaceutical Industry

Jinfang Medicine Launches Phase III Trial for GFH375

Jinfang Pharmaceutical-B Completes First Patient Enrollment in GFH375 Combination Therapy Study

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02655

00650

01347

02637

02198

00981

01989

09903

02595

01772

GUOXIA TECH(02655) rose 33.79%, with a trading turnover 1.9 Billion HKD, and a year-to-date fell 10.4%. PRODUCTIVE TECH(00650) rose 27.71%, with a trading turnover 57.5 Million HKD, and a year-to-date rose 181.9%. HUA HONG SEMI(01347) rose 15.18%, with a trading turnover 8.5 Billion HKD, and a year-to-date rose 45.5%.

Top Gainers&Losers

GUOXIA TECH

PRODUCTIVE TECH

HUA HONG SEMI

HAIXI PHARMA

CHINA SANJIANG

SMIC

DELTON

ILUVATAR COREX

GANFENGLITHIUM

Top 10 HK Stock Gainers (4.24)

02517

06656

09887

01384

02656

06660

03986

02788

GUOXIA TECH(02655) fell 24.04%, with a trading turnover 653.6 Million HKD, and a year-to-date rose 9.2%. GUOQUAN(02517) fell 11.17%, with a trading turnover 338.8 Million HKD, and a year-to-date fell 13.4%. SIGENERGY(06656) fell 9.02%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 85.1%.

GUOQUAN

SIGENERGY

LEADS BIOLABS-B

DEEPEXI TECH

160 HEALTH

AIM VACCINE

GIGADEVICE

CHUANGXIN IND

Top 10 HK Stock Losers (4.17)

GENFLEET-B rose 18.65%; Innovent Biologics rose 0.29%, with a transaction amount reaching HKD 173 million; BeiGene fell 0.80%, with a transaction amount reaching HKD 158 million; CanSino Biologics rose 0.94%, with a transaction amount reaching HKD 151 million; Kelun-Biotech fell 0.37%, with a market value of HKD 113.2 billion

HK Stock Alerts

Hong Kong stock movement: GENFLEET-B rises 18.65%, with clear capital flow, market sentiment triggers volatility attention

02729

03317

01872

00568

02526

02635

03625

GALAXIS TECH(02729) rose 24.63%, with a trading turnover 49.1 Million HKD, and a year-to-date rose 139.4%. XUNCE(03317) rose 23.92%, with a trading turnover 2.8 Billion HKD, and a year-to-date rose 470.3%. GUAN CHAO HLDGS(01872) rose 10.89%, with a trading turnover 38.2 Million HKD, and a year-to-date rose 0.4%.

GALAXIS TECH

XUNCE

GUAN CHAO HLDGS

SHANDONG MOLONG

DIAGENS-B

NUOBIKAN

FOURSEMI

Top 10 HK Stock Gainers (4.9)

513700

GENFLEET (##2595.HK##) has recently faced continuous pressure on its stock price, showing a clear downward trend, which has attracted widespread attention in the market. Analyzing the technical indicators, the MACD has formed a death cross, and selling pressure is continuously increasing, making it difficult for bulls to launch an effective counterattack. From the market structure perspective, the pharmaceutical sector where GENFLEET is located has shown weak performance recently, with low liquidity of funds within the sector, coupled with reduced market confidence due to policy uncertainties, all of which have significantly impacted its stock price. The company has not been able to find effective driving factors to boost performance in the short term, leading to a strong wait-and-see sentiment in the market. It is worth mentioning that although GENFLEET has made arrangements in research and development, the cycle for actualizing results is long, and its ability to attract funds in the short term is limited, making it difficult to quickly change the current downward trend. The impact of the external economic environment cannot be ignored either, as the international market situation is transmitting risks to the pharmaceutical industry. In this context, investors should pay attention to controlling investment risks, closely monitor policy changes and international market trends, and timely capture potential investment opportunities. However, considering the frequent negative factors recently, it is advisable to avoid blindly bottom-fishing and to wait for clearer rebound signals for confirmation. Additionally, it is important to focus on flexible allocation of funds and setting stop-loss measures to cope with various market risks that may arise

Technical Forecast

Penghua CSI HK Connect Health Care Composite ETF

Morning Trend | GENFLEET-B Under Pressure, When Will It Welcome a Rebound Opportunity?

520880

159506

520690

159316

GenFleet Therapeutics has updated its Board Nomination Committee terms to enhance governance, effective March 24, 2026. The committee, primarily composed of independent non-executive directors, will oversee board structure, succession planning, and diversity policy. Responsibilities include annual reviews of board size and skills, director selection criteria, and performance assessments. The committee can seek independent advice, aiming for transparent oversight and alignment with corporate governance standards in Hong Kong. GenFleet, a biopharmaceutical company listed in Hong Kong, focuses on innovative therapeutics and adheres to local listing rules and corporate law.

Tip Ranks

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GenFleet Tightens Board Nomination Rules to Strengthen Governance

GENFLEET announced that it will present preclinical research data for three products, including GFH276, GFS784, and GFH603, at the 2026 AACR Annual Meeting. The conference will be held from April 17 to 22 in San Diego, USA, and the company's presentations will take place on April 19 and 21

AASTOCKS

First Trust NYSE Arca Biotech Index Fd

GENFLEET will present preclinical research data for three products at the AACR annual meeting

00856

02331

03808

03750

03858

00325

06088

00666

01440

GENFLEET-B(02595) rose 11.31%, with a trading turnover 347.8 Million HKD, and a year-to-date rose 21.7%. VSTECS(00856) rose 11.04%, with a trading turnover 582.7 Million HKD, and a year-to-date rose 12.2%. LI NING(02331) rose 8.56%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 14.8%.

GENFLEET-B(02595.HK)